Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19

alexandrossfakianakis shared this article with you from Inoreader Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19 via Clinical Infectious Diseases Advance Access Abstract COVID-19 convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immune compromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-titer SARS-CoV-2 antibodies, retains activity against circul ating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.